TOKYO, March 10, 2026 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI®), Eisai's anti-amyloid beta (Aβ) protofibril antibody for the treatment...
Hence then, the article about eisai to present the latest data on long term real world treatment with lecanemab at the ad pd 2026 annual meeting was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD™ 2026 Annual Meeting )
Also on site :
- Atera Declares an End to Workplace Tech Bottlenecks, Expands Global Enterprise Growth With Launch of Robin by Atera and 'Let People Work' Campaign
- Saudi Aramco Sees 1.1 Million Bpd Oil Demand Growth in 2026
- Trump's Clean Energy 'Assault' Sinks Solar Installation Numbers